1. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility;Hughes;Pharmacogenom J,2008
2. Pharmacogenetics in drug discovery and development: a translational perspective;Roses;Nat Rev Drug Discov,2008
3. (CDER), C.f.D.E.a.R., C.f.B.E.a.R. (CBER), and C.f.D.a.R.H. (CDRH), Draft Guidance: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, U.S.D.o.H.a.H. Services and F.a.D. Administration, Editors. 2012, Office of Communication, Outreach and Development v http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm.
4. (CDER), C.f.D.E.a.R. and C.f.B.E.a.R. (CBER), Guidance for Industry: E15 Definitions for Genomic Biomarkers, Pharmacogenomics. Pharmacogenetics, Genomic Data and Sample Coding Categories. U.S.D.o.H.a.H. Services and F.a.D. Administration, Editors. 2008: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073162.pdf.
5. Characterization of the poly-T variant in the TOMM40 gene in diverse populations;Linnertz;PLoS ONE,2012